These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34054800)

  • 1. Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program.
    Lee CY; Tseng CJ; Chang CC; Lee MC; Yang SF
    Front Immunol; 2021; 12():626582. PubMed ID: 34054800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Have preferences of girls changed almost 3 years after the much debated start of the HPV vaccination program in The Netherlands? A discrete choice experiment.
    Hofman R; de Bekker-Grob EW; Richardus JH; de Koning HJ; van Ballegooijen M; Korfage IJ
    PLoS One; 2014; 9(8):e104772. PubMed ID: 25136919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptance and compliance with postpartum human papillomavirus vaccination.
    Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
    Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative and qualitative assessment of an all-inclusive postpartum human papillomavirus vaccination program.
    Berenson AB; Hirth JM; Kuo YF; Rupp RE
    Am J Obstet Gynecol; 2021 May; 224(5):504.e1-504.e9. PubMed ID: 33248134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient.
    Guo F; Hirth JM; Berenson AB
    J Womens Health (Larchmt); 2017 Oct; 26(10):1114-1122. PubMed ID: 28841084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human papillomavirus vaccination program for low-income postpartum women.
    Berenson AB; Rahman M; Hirth JM; Rupp RE; Sarpong KO
    Am J Obstet Gynecol; 2016 Sep; 215(3):318.e1-9. PubMed ID: 26899907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting.
    Mabeya H; Menon S; Weyers S; Naanyu V; Mwaliko E; Kirop E; Orango O; Vermandere H; Vanden Broeck D
    BMC Cancer; 2018 May; 18(1):557. PubMed ID: 29751793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis.
    Drolet M; Laprise JF; Chamberland É; Sauvageau C; Wilson S; Lim GH; Ogilvie G; Tuite A; Brisson M
    CMAJ; 2024 Oct; 196(33):E1136-E1143. PubMed ID: 39374971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with HPV vaccination among adult women in Quebec.
    Kiely M; Sauvageau C; Dubé E; Deceuninck G; De Wals P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1421-4. PubMed ID: 23571165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.